Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:awards |
Best Startup
Innovative_Company_Award |
| gptkbp:CEO |
gptkb:M._A._(Tony)_T._Tizon
|
| gptkbp:clinicalTrials |
ongoing
|
| gptkbp:collaborations |
academic institutions
|
| gptkbp:focus |
immuno-oncology
|
| gptkbp:founded |
2015
|
| gptkbp:headquarters |
gptkb:San_Carlos,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tizona Therapeutics
|
| gptkbp:investmentFocus |
gptkb:The_Venture_Reality_Fund
gptkb:Canaan_Partners Kleiner Perkins |
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:products |
gptkb:TTX-030
TTX-040 |
| gptkbp:research_focus |
cancer therapy
tumor microenvironment immune checkpoint inhibitors |
| gptkbp:technology |
T cell engagers
|
| gptkbp:type |
private company
|
| gptkbp:website |
www.tizonatherapeutics.com
|